GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Biosyent (TSXV:RX) Future 3-5Y EPS without NRI Growth Rate : 20.38 (As of Jan. 18, 2025)


View and export this data going back to 1979. Start your Free Trial

What is Biosyent Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Biosyent's Future 3-5Y EPS without NRI Growth Rate is 20.38.

Competitive Comparison of Biosyent's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biosyent's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Biosyent's Future 3-5Y EPS without NRI Growth Rate falls into.


Biosyent  (TSXV:RX) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Biosyent Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Biosyent's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
TSX:HLS TSX:CRDL XCNQ:AAWH.U TSXV:SBBC XCNQ:PLTH XCNQ:VREO TSX:MDP XCNQ:JUSH TSXV:LOVE XCNQ:AYR.A ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
BIOYF:USA
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Website
http://www.biosyent.com
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.
Executives
Fax Investments Inc. 10% Security Holder
Peter Douglas Lockhard Director
Seyed Ahmad Ashrafi Director
Sharan Raghubir Senior Officer
Rene Goehrum 10% Security Holder, Director, Senior Officer
Biosyent Inc. Issuer
Fax Capital Corp. 10% Security Holder
Joost Van Der Mark Senior Officer
Robert Joseph March Senior Officer
Sara Elford Director
Alfred D'souza Director

Biosyent Headlines

No Headlines